Skip to main content

VAV Response in AVNRT

Vav response observed in avnrt


 During an electrophysiology (EP) study for typical AVNRT (Atrioventricular Nodal Reentrant Tachycardia), a VAV (Ventriculo-Atrial-Ventricular) response can be a crucial diagnostic finding.


What is a VAV response?

A VAV response occurs when a ventricular extrastimulus (a premature ventricular beat) is introduced during the tachycardia. This extrastimulus conducts retrogradely (backward) to the atrium, causing atrial activation (A). Subsequently, the atrium activates the ventricle again through the AV node, resulting in another ventricular activation (V).


Why is the VAV response important in AVNRT?

The VAV response helps diagnose AVNRT and differentiate it from other supraventricular tachycardias. In AVNRT, the VAV response typically demonstrates:


1. Retrograde conduction: The ventricular extrastimulus conducts backward to the atrium, indicating the presence of a retrograde pathway (usually the fast pathway).

2. Anterograde conduction: The subsequent atrial activation conducts down the slow pathway, resulting in another ventricular activation.


What does the VAV response indicate?

The VAV response indicates that the tachycardia is likely due to AVNRT, involving a reentrant circuit within the AV node. This response can help:


1. Confirm the diagnosis: The VAV response supports the diagnosis of AVNRT.

2. Guide ablation: The VAV response can help identify the target for ablation, typically the slow pathway.


The VAV response is a valuable diagnostic tool in EP studies, providing insights into the mechanism of AVNRT and guiding effective treatment.


#Electrophysiology



Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.